Adtran wins two FTTH Innovation Awards for 50G PON and deep PON fiber monitoring
News summary: Adtran’s 50G PON fiber access solution and fiber monitoring platform recognized for their impact on advancing fiber broadband connectivity SDX 6405 OLT supports coexistence of GPON, XGS-PON and 50G PON on each port for seamless network scaling ALM with deep PON assurance delivers real-time, in-service fiber monitoring, enhancing network reliability and reducing opex costs
Adtran today announced that it has won two FTTH Innovation Awards at the FTTH Conference 2025, recognizing its SDX 6405 optical line terminal (OLT) and ALM fiber monitoring platform as standout technologies supporting next-generation fiber networks. Organized by the FTTH Council Europe, the annual awards highlight innovations that accelerate fiber broadband rollouts while improving scalability, operational efficiency and user experience. Adtran received awards in two categories: ‘Active infrastructure – central network’ and ‘Installation equipment, tools, test & measurement instruments.’
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250326874284/en/
Adtran’s SDX 6405 OLT and ALM fiber monitoring platform received Innovation Awards at the FTTH Conference 2025.
“We’re honored to receive this recognition at the FTTH Conference. It’s a fantastic achievement for our team and a validation of the vision that’s guided our work: to help service providers build fiber networks that are open, scalable and ready for what comes next,” said Christoph Glingener, CTO of Adtran. “These wins reflect the dedication and expertise across our organization – from engineering to product to field support – and the close partnerships we’ve built with customers to solve real deployment challenges. Whether it’s enabling a future-proof transition to 50G PON or delivering affordable, real-time visibility into the access network, we’re focused on giving operators the tools to grow efficiently, improve reliability and stay ahead of demand.”
Adtran’s SDX 6405 won in the central network category for its 50G PON capabilities and disaggregated architecture. Part of the SDX 6000 Series, it supports GPON, XGS-PON and 50G PON on every port, enabling providers to deliver multigigabit services for residential, business and backhaul use cases – all over a single fiber. Its modular design eliminates the trade-off between near-term cost and long-term scalability. With the SDX 6405, providers can gradually add 50G OLTs to meet growing demand without disrupting existing subscribers or overhauling infrastructure. Built on an open, software-defined architecture, it integrates seamlessly into multivendor networks and supports automated service delivery through Adtran’s Mosaic Cloud Platform.
In the tools and measurement category, Adtran’s ALM was recognized for redefining how service providers monitor and manage fiber infrastructure. The compact, low-power device offers real-time, in-service visibility across the entire optical plant – enabling operators to detect and pinpoint issues before they affect customers. A key innovation is its deep PON assurance capability, which makes it possible to monitor fiber behind splitters without the need for demarcation reflectors. This is especially valuable for FTTH deployments, where scale and complexity can make fault detection and resolution a significant operational challenge. With support for fixed and mobile access networks, ALM empowers operators to increase service quality while lowering operational costs.
“These two awards recognize technologies that are solving critical challenges in access networks – from scaling bandwidth to ensuring new levels of service reliability,” commented Robert Conger, GM of software platforms and strategy at Adtran. “With 50G PON, we’re enabling a new generation of services that demand ultra-fast, highly reliable connectivity – whether that’s AI workloads, immersive experiences or industrial automation. At the same time, it delivers lower-speed services like 1G and 10G far more efficiently, helping operators simplify their access infrastructure and maximize return on investment. And with deep PON assurance, we’re giving operators the visibility they need to maintain those services at scale. It’s about building the foundation for sustainable, high-performance broadband that can evolve with demand.”
About Adtran
ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the majority shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250326874284/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom